Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atezolizumab + vismodegib
- Development stage
- Phase 2
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination therapy consisting of atezolizumab, a PD-L1 inhibitor immunotherapy, and vismodegib, a Hedgehog pathway inhibitor. This combination is being investigated in clinical trials for the treatment of various cancers, including platinum-resistant ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. The combination aims to leverage the immune-enhancing effects of atezolizumab with the tumor-reducing capabilities of vismodegib.
- Other names
- vismodegib + atezolizumab combination
02
Targets
Beyond the preview
Go deeper on atezolizumab + vismodegib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atezolizumab + vismodegib.